Our biomarker for out-licensing

DPP3 biomarker guides doctors to act on the right information at the right time in intensive care units. 
It is available for out-licensing to global In-Vitro Diagnostics and pharmaceutical companies.

6 Patent families covering the use of DPP3 biomarker for various medical purposes


The DPP3 biomarker has been out-licensed to SphingoTec GmbH to be measured using Nexus IB10 Point of care.
SphingoTec GmbH
Adrenomed AG evaluted DPP3 plasma levels in a prespecified analysis in the phase II trial and will use DPP3 for a planned phase III trial as an exclusion criterion for the patient selection
Adrenomed AG